We are live on ! Find out more
BC

Broadfin Capital Portfolio holdings

AUM $747M
1-Year Est. Return 100.56%
This Fund
S&P 500
This Quarter Est. Return
+10.7%
1 Year Est. Return
+100.56%
3 Year Est. Return
+297.65%
5 Year Est. Return
+365.91%
10 Year Est. Return
–
AUM
$680M
AUM Growth
+$44.3M
Cap. Flow
+$13.8M
Cap. Flow %
2.03%
Top 10 Hldgs %
51.48%
Holding
61
New
16
Increased
14
Reduced
12
Closed
11

Top Buys

Rank Stock Value
1
LJPC
La Jolla Pharmaceutical Company
LJPC
+$14.6M
2
NSTG
NanoString Technologies, Inc.
NSTG
+$12.4M
3
IOVA icon
Iovance Biotherapeutics
IOVA
+$10.6M
4
XENE icon
Xenon Pharmaceuticals
XENE
+$10.4M
5
XENT
Intersect ENT, Inc
XENT
+$7.03M

Top Sells

Rank Stock Value
1
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$36.9M
2
ENDP
Endo International plc
ENDP
+$24.4M
3
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$17.7M
4
EXAS
Exact Sciences
EXAS
+$15.6M
5
XRAY icon
Dentsply Sirona
XRAY
+$11.5M

Sector Composition

Rank Sector Weight
1 Healthcare 72.76%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
IWM icon
1
PUT
iShares Russell 2000 ETF
IWM
$81.6B
$67.4M 9.92%
+400,000
New +$67.5M
IOVA icon
2
Iovance Biotherapeutics
IOVA
$2.25B
$55.1M 8.1%
4,894,361
+747,756
+18% +$10.6M
LJPC
3
DELISTED
La Jolla Pharmaceutical Company
LJPC
$41.3M 6.08%
2,053,991
+559,471
+37% +$14.6M
ZGNX
4
DELISTED
Zogenix, Inc.
ZGNX
$32.6M 4.8%
657,898
+35,518
+6% +$1.81M
ADMA icon
5
ADMA Biologics
ADMA
$2.03B
$27.7M 4.08%
4,463,829
+1,214,000
+37% +$6.99M
TVTX icon
6
Travere Therapeutics
TVTX
$5.19B
$27M 3.97%
938,214
-110,479
-11% -$3.16M
ADMS
7
DELISTED
Adamas Pharmaceuticals
ADMS
$26.6M 3.91%
1,328,424
-88,697
-6% -$2.08M
TNDM icon
8
Tandem Diabetes Care
TNDM
$1.23B
$24.6M 3.61%
573,079
+2,481
+0.4% +$86.6K
PETX
9
DELISTED
Aratana Therapeutics, Inc.
PETX
$23.8M 3.51%
4,083,135
-211,291
-5% -$1.06M
AMRN
10
CALL
Amarin Corp
AMRN
$287M
$23.7M 3.48%
72,750
– –
CORI
11
DELISTED
Corium International, Inc.
CORI
$22.5M 3.31%
2,368,557
-1,228,500
-34% -$10.6M
CPRX
12
DELISTED
Catalyst Pharmaceutical
CPRX
$19.4M 2.86%
5,136,264
-1,636,500
-24% -$5.13M
MRTX
13
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$16.8M 2.48%
357,672
-662,506
-65% -$36.9M
ATRS
14
DELISTED
Antares Pharma, Inc.
ATRS
$15.5M 2.29%
4,623,247
– –
XBI icon
15
PUT
State Street SPDR S&P Biotech ETF
XBI
$10.3B
$15.3M 2.26%
+160,000
New +$15.5M
NSTG
16
DELISTED
NanoString Technologies, Inc.
NSTG
$15.2M 2.23%
+850,000
New +$12.4M
SCTL
17
DELISTED
Societal CDMO, Inc. Common Stock
SCTL
$14.6M 2.14%
2,283,548
– –
PACB icon
18
Pacific Biosciences
PACB
$419M
$13.5M 1.98%
2,493,021
+1,438,930
+137% +$6.17M
IART icon
19
Integra LifeSciences
IART
$1.5B
$12.9M 1.91%
196,572
+33,148
+20% +$2.06M
SBBP
20
DELISTED
Strongbridge Biopharma plc.
SBBP
$12.4M 1.83%
2,563,096
+222,447
+10% +$1.14M
AVDL
21
DELISTED
Avadel Pharmaceuticals
AVDL
$12.3M 1.8%
2,792,773
+68,110
+2% +$368K
BDSI
22
DELISTED
BioDelivery Sciences International, Inc.
BDSI
$12.3M 1.8%
4,375,066
+96,247
+2% +$270K
TLGT
23
DELISTED
Teligent, Inc
TLGT
$12.1M 1.77%
305,285
+5,303
+2% +$212K
XENE icon
24
Xenon Pharmaceuticals
XENE
$6.51B
$11.8M 1.74%
+895,553
New +$10.4M
HRTX icon
25
Heron Therapeutics
HRTX
$90.7M
$9.22M 1.36%
291,213
-228,574
-44% -$8.51M
1
2 3

Similar funds

CBU
CIBC Bank USA Chicago, Illinois $756M AUM 24.68% 1-Year Est. Return
CONA
Capital One National Association New York $756M AUM
MP
Manikay Partners New York $893M AUM 55.39% 1-Year Est. Return
SC
Selz Capital New York $570M AUM 35.56% 1-Year Est. Return
KGACF
Kopernik Global All-Cap Fund Tampa, Florida $558M AUM
BPWA
Beacon Pointe Wealth Advisors Newport Beach, California $543M AUM 23.61% 1-Year Est. Return
TRAM
Tuscan Ridge Asset Management Chicago, Illinois $984M AUM 25.8% 1-Year Est. Return
VMI
VHCP Management III New York $504M AUM 683.12% 1-Year Est. Return

Broadfin Capital's Q3 2018 Portfolio in Review

As of Q3 2018, Broadfin Capital held 61 positions worth $680M, up 7% from $635M the previous quarter. Its ten largest holdings account for 51% of the portfolio.

Broadfin Capital's Q3 2018 filing shows 16 new, 14 increased, 12 reduced and 11 closed positions. Its largest new stake was NanoString Technologies, Inc.: 850,000 shares worth $15.2M. The largest sale was Mirati Therapeutics, Inc. Common Stock, an estimated $36.9M.

By sector, the portfolio is most concentrated in Healthcare at 73% of assets, down from 84% a quarter earlier.

  • Broadfin Capital's largest Q3 2018 buy was NanoString Technologies, Inc.: 850,000 shares worth $15.2M.
  • Broadfin Capital added most to La Jolla Pharmaceutical Company in Q3 2018, an estimated $14.6M increase.
  • Broadfin Capital's biggest Q3 2018 reduction was Mirati Therapeutics, Inc. Common Stock, cutting an estimated $36.9M.
  • Broadfin Capital fully exited Endo International plc in Q3 2018, selling an estimated $24.4M.
  • Broadfin Capital's ten largest holdings make up 51% of its $680M portfolio in Q3 2018.
  • Broadfin Capital opened 16 new positions and closed 11 in Q3 2018.
  • Broadfin Capital's portfolio value rose 7% quarter-over-quarter to $680M.

Based on Broadfin Capital's 13F filing for Q3 2018, filed 14 Nov 2018.